TABLE 1

VT-1129 and fluconazole MICs against Cryptococcus neoformans isolatesa

ParameterMIC for agent (endpoint)UTHSCSA MIC over lower concn range of VT-1129 (n = 54)
Cumulative (n = 180)CDC (n = 100)UTHSCSA (n = 80)
VT-1129 (50%)VT-1129 (100%)FLU (50%)VT-1129 (50%)VT-1129 (100%)FLU (50%)VT-1129 (50%)VT-1129 (100%)FLU (50%)VT-1129 (50%)VT-1129 (100%)FLU (50%)
Range≤0.015–2≤0.015–40.25–>64≤0.015–0.125≤0.015–20.5–16≤0.015–2≤0.015–40.25–>640.004–>0.250.015–>0.25≤0.125–>64
Mode≤0.0150.252≤0.0150.54≤0.0150.12520.0080.252
MIC50≤0.0150.252≤0.0150.252≤0.0150.12520.0080.252
MIC900.060.580.060.580.060.580.06>0.258
GM MICb0.02710.20522.2800.02640.29972.2500.02810.12782.3170.01260.15192.488
  • a All MICs were measured after 72 h of incubation at 35°C. VT-1129 MICs were read at 50% and 100% inhibition of growth compared to growth control. Fluconazole (FLU) MICs were measured at 50% inhibition of growth. Fluconazole MICs for CDC isolates are historical values.

  • b GM MIC, geometric mean MIC.